Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00182455
Status:
TERMINATED
Last Update Posted:
2020-09-02
First Post:
2005-09-14
Brief Title:
Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia GSP
Sponsor:
McMaster University
Organization:
McMaster University
Study Overview
Official Title:
Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor SSRI in Treatment-Resistant Generalized Social Phobia A Double-Blind Placebo -Controlled Trial
Status:
TERMINATED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
loss of funding
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
SSRIs are considered first-line treatments for GSP however many patients continue to have significant symptoms despite an adequate trial of an SSRI Topiramate a drug which targets the glutamate system in the brain has been shown to improve symptoms of social phobia when used on its own and has also been used as an additive treatment in other anxiety disorders This study will test the efficacy of adding topiramate to a subjects current SSRI in cases of GSP which are considered to be treatment-resistant
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None